What Attana does

Attana is a Swedish biotechnology company headquartered in Stockholm that has developed proprietary third-generation biosensor technology for measuring how drug candidates bind to biological targets over time. Founded in 2002 and publicly listed on the NGM Growth Market under the ticker ATANA, the company operates with 11–50 employees and addresses the drug development value chain by providing binding kinetics testing that is positioned as a more realistic assessment than traditional endpoint binding assays. The platform is intended to help pharmaceutical and biotechnology developers select better drug candidates before committing capital to expensive clinical trial phases, with the explicit value proposition of reducing late-stage drug research failure rates.

The company's go-to-market is in active transition. Historically a research-oriented entity, Attana is repositioning to serve contract research organizations (CROs), pharmaceutical companies, and biotechnology firms through a subscription-based rental model that allows laboratories to access the binding kinetics technology without the upfront capital outlay of instrument purchase. Distribution is direct-to-laboratory, and a key patent approval was secured in Q1 2026 to underpin the commercial push. Primary customer segments are horizontal use cases — drug candidate selection, binding kinetics testing, and diagnostic analysis for drug development — rather than a single named anchor vertical.

Attana's financial profile reflects an early-stage commercial operation. Q1 2026 results disclosed declining sales and widened losses as the company invested in the CRO pivot, and in June 2026 the company raised approximately 24.2 million SEK via a preferential share emission (rights issue) secured largely through subscription commitments and a directed convertible to the main owner. The company currently serves customers primarily in Europe, and management has not publicly disclosed pricing or specific customer logos, leaving revenue concentration and absolute scale unverified.

Name

Attana

Legal name

Attana

Website

https://attana.com

Company type

Public

Founded year

2002

Operating status

Operating

Headcount range

11–50 employees

Short description

Attana is a Swedish biotech company that develops proprietary third-generation biosensor technology for measuring drug candidate binding kinetics, serving pharmaceutical developers and CROs seeking better candidate selection before clinical trials.

Ownership category

akta.pro rank

Product category

Biosensor Instruments

NAICS

Analytical Laboratory Instrument Manufacturing (334516), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Laboratory Analytical Instruments (3826), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Preclinical CROs (Discovery/Pharmacology/DMPK) (HLAGAAAB)

akta.pro secondary industry

Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity) (HLAGAAAD)

Keywords

• Binding kinetics analysis
• Biosensor technology
• Drug candidate screening
• Preclinical testing services
• Biopharmaceutical analytics

Headquarters

HQ city

Stockholm

HQ country

Sweden

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

1. Technology Rental/Subscription Services: Attana offers its binding kinetics testing technology to pharmaceutical and biotech laboratories through a rental model, generating recurring subscription revenues. This allows laboratories to access advanced testing without purchasing expensive instruments upfront.

Go-to-market motion2 records

Distribution channels1 record

Core offering

Attana develops and commercializes proprietary third-generation biosensor instruments that measure how drug candidates bind to biological targets over time. The company provides its binding kinetics testing technology to pharmaceutical, biotech, and contract research organization (CRO) laboratories, primarily through a subscription-based rental model that allows labs to use the technology without purchasing expensive instruments upfront.

Product overview

Attana is a Swedish biotech company that has developed proprietary binding kinetics testing technology. The company offers instruments that measure how drug candidates bind over time, providing a more realistic assessment than traditional testing methods. Attana is transitioning from a pure research entity toward offering its technology as a scalable, subscription-based rental service to pharmaceutical and biotech laboratories (CRO market). The company aims to help drug developers select better candidates before expensive clinical trial phases by providing advanced testing methods that reduce failure rates in drug research.

Differentiator

Problem solved

Functional benefit

Products and services

• Attana Biosensor Instruments

Quantifiable outcome

• Reduces failure rate in drug research
• +1 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Scale indicators2 records

Recent moves9 records

Expansion highlights5 records

Broad incumbents

• Bio-Rad Laboratories: Bio-Rad supplies life-science research and clinical diagnostics instruments, including surface plasmon resonance and protein interaction tools used in pharma and academic labs alongside Attana's biosensor customers.
• Waters Corporation: Waters manufactures analytical instruments (chromatography, mass spectrometry) widely used in pharma R&D and QC; while not a direct binding kinetics competitor, it shares the same instrument-purchasing customer base.
• Lonza: Lonza is a major CDMO/CRO serving pharma with discovery, manufacturing, and analytical services; representative of the large CRO/CMO customers Attana aims to reach with its subscription rental model.
• Cytiva (formerly GE Healthcare Life Sciences): Cytiva's Biacore label-free SPR platform is the dominant reference standard for binding kinetics and specificity analysis; directly comparable technology competing for the same CRO and pharma R&D accounts Attana targets.
• Bruker: Bruker manufactures a broad portfolio of analytical and life-science instruments, including mass spectrometry and SPR platforms used for binding and molecular interaction studies in pharma and biotech labs.

Emerging players

• Repligen: Repligen provides bioprocessing and analytics products, including SPR-based binding kinetics consumables, serving biopharma process development and analytical labs with adjacent offerings to Attana.
• Evotec: Evotec is a drug discovery CRO with end-to-end preclinical capabilities, including in vitro pharmacology and binding assays; comparable as both a potential CRO customer for Attana and a competing preclinical service provider.

Direct peers

• Carterra: Carterra provides high-throughput label-free SPR (LSA) instruments for antibody and binding kinetics characterization, directly competing with Attana's biosensor technology in preclinical drug discovery applications.
• Charles River Laboratories: Charles River is a large preclinical CRO offering discovery and pharmacology services; it represents the customer archetype Attana is targeting and also a potential commercialization partner or competitor in binding analytics.
• Sartorius (including FortéBio / Octet): Sartorius's Octet (FortéBio) systems are a leading label-free binding kinetics platform used in drug discovery and CRO workflows, directly overlapping Attana's biosensor offering for antibody and small-molecule characterization.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/attana-ab

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Attana